Top Page
Predictive Oncology
(NASDAQ:POAI)
Predictive Oncology (POAI) vs. SPDR S&P 500 ETF (SPY)
Predictive Oncology Business Overview & Revenue Model
Predictive Oncology Earnings Call Summary
Predictive Oncology Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 728.20K | 1.62M | 1.63M | 1.51M | 1.42M | 1.25M |
| Gross Profit | 365.87K | 797.68K | 1.02M | 1.00M | 933.66K | 805.08K |
| EBITDA | -83.09M | -10.24M | -11.87M | -13.95M | -12.13M | -11.46M |
| Net Income | -84.33M | -12.20M | -13.98M | -25.74M | -19.66M | -25.88M |
Balance Sheet | ||||||
| Total Assets | 3.14M | 4.97M | 14.42M | 25.73M | 43.77M | 13.06M |
| Cash, Cash Equivalents and Short-Term Investments | 181.67K | 734.67K | 8.73M | 22.07M | 28.20M | 678.33K |
| Total Debt | 1.70M | 2.13M | 2.73M | 180.32K | 879.33K | 5.87M |
| Total Liabilities | 80.57M | 5.18M | 6.15M | 3.97M | 3.51M | 10.42M |
| Stockholders Equity | -77.43M | -202.61K | 8.27M | 21.77M | 40.27M | 2.64M |
Cash Flow | ||||||
| Free Cash Flow | -8.78M | -11.97M | -13.21M | -12.85M | -13.17M | -12.62M |
| Operating Cash Flow | -8.78M | -11.96M | -13.19M | -12.37M | -12.21M | -12.26M |
| Investing Cash Flow | 657.00K | 22.49K | -302.37K | -475.70K | -10.61M | -167.46K |
| Financing Cash Flow | 4.36M | 3.94M | 148.90K | 6.72M | 50.34M | 12.95M |
Predictive Oncology Technical Analysis
Predictive Oncology Risk Analysis
Predictive Oncology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $7.02M | 40.95 | 5.90% | ― | -4.99% | -19.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $53.80M | ― | -376.23% | ― | 63.53% | 12.49% | |
47 Neutral | $14.46M | -0.04 | ― | ― | -47.20% | -163.70% | |
44 Neutral | $17.40M | -0.92 | -85.01% | ― | -16.59% | 43.20% | |
41 Neutral | $3.78M | ― | ― | ― | ― | ― | |
28 Underperform | $5.54M | >-0.01 | ― | ― | ― | 60.83% |
Predictive Oncology Corporate Events
On December 10, 2025, Axe Compute Inc. amended the employment agreement with CEO Raymond F. Vennare, increasing his salary and outlining bonus eligibility. On December 12, 2025, the company announced its name change to Axe Compute Inc. and began trading on Nasdaq under the ticker AGPU. The company plans to expand its operations into high-performance AI infrastructure, positioning itself as a key player in addressing the infrastructure bottleneck in AI development by utilizing the Aethir network to provide scalable GPU capacity.
Predictive Oncology Inc., a company involved in the field of oncology, has announced a corporate name change to Axe Compute Inc., effective December 11, 2025. This change, approved by the Board of Directors, does not require stockholder approval and involves the adoption of amended bylaws. The company’s stock will trade under the new ticker symbol ‘AGPU’ on Nasdaq starting December 12, 2025, with no changes to the CUSIP number or the validity of existing stock certificates.
On December 1, 2025, Predictive Oncology Inc. announced that it had regained compliance with Nasdaq’s minimum stockholders’ equity requirement, allowing its shares to continue trading on the Nasdaq Capital Market. This compliance reflects the company’s recent progress in strengthening its financial position and supports its long-term vision, including its digital asset strategy focused on the Aethir ecosystem. The company will be monitored by Nasdaq for a year, and any future non-compliance could lead to a delisting determination.
At the Annual Meeting, Predictive Oncology‘s stockholders voted on several key proposals. The election of Class I directors, including Daniel E. Handley and Chuck Nuzum, was confirmed to serve until the 2028 Annual Meeting. Additionally, KPMG LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Stockholders also approved an amendment and the issuance of 14,903,393 shares upon the exercise of pre-funded warrants. Furthermore, a non-binding advisory vote approved the compensation of the company’s named executive officers.
Predictive Oncology Inc. has announced that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement following two private investment in public equity transactions. The company received approximately $343.5 million, which included cash and in-kind contributions of crypto assets, bringing its stockholders’ equity above the required $2.5 million threshold.
On November 17, 2025, Predictive Oncology Inc. held a conference call to discuss its third-quarter financial results and its new digital asset strategy. The company is aligning with the Aethir network to capitalize on the growing AI infrastructure market, projected to reach $2.8 trillion by 2029. This strategic move aims to enhance the company’s access to advanced computing power and create new revenue streams through digital assets, potentially impacting its market positioning and stakeholder value.
On October 29, 2025, Predictive Oncology Inc. filed a prospectus supplement to update its at-the-market (ATM) offering program, allowing the sale of up to $18,330,000 in common stock. This move aims to adjust the maximum share sales under the ATM program, contingent on changes in the company’s public float, which could impact its ability to raise capital and expand its operations.
Predictive Oncology has scheduled its 2025 annual meeting of stockholders for November 25, 2025, at DLA Piper LLP’s offices in Pittsburgh, Pennsylvania. The company has set October 24, 2025, as the record date for determining stockholders eligible to vote. Stockholders have until October 26, 2025, to submit proposals for consideration at the meeting. The company plans to distribute proxy materials around November 3, 2025, and may adjust these materials or the meeting date based on proposals received.
On October 8, 2025, Predictive Oncology announced the closing of two private placements totaling approximately $343.5 million, which occurred on October 7, 2025. The funds will support the company’s new digital asset treasury strategy focused on ATH, a utility token of the Aethir ecosystem. This initiative aligns with Predictive Oncology’s AI-driven drug discovery efforts and aims to enhance Aethir’s infrastructure for AI and machine learning globally. The strategic move is expected to create significant value for the company and its shareholders.
Predictive Oncology Inc., a Delaware corporation, announced on September 29, 2025, that it entered into securities purchase agreements with accredited investors for private placements involving cash and cryptocurrency offerings. The company plans to issue common stock and pre-funded warrants, with the proceeds primarily used to establish a cryptocurrency treasury strategy focusing on digital assets like Aethir tokens. This strategic move aims to enhance the company’s financial positioning and operational capabilities, while also initiating a digital asset treasury strategy to manage and acquire digital assets. Additionally, changes in the board of directors were announced, with Nancy Chung-Welch resigning and Shawn Matthews being appointed, reflecting the company’s strategic alignment with its new digital asset focus.
On September 29, 2025, Predictive Oncology Inc. announced two private placements totaling $344.4 million to support its new digital asset treasury strategy, focusing on Aethir (ATH) tokens. This strategic move aims to enhance the company’s operations by leveraging Aethir’s decentralized GPU network, potentially strengthening its market position and offering significant growth opportunities. The company plans to use the proceeds to acquire ATH tokens and fund general corporate purposes, with DNA Holdings Venture, Inc. as a strategic advisor. This initiative marks a significant step in Predictive Oncology’s expansion into digital assets, aligning with its core business of AI-driven drug discovery.
On September 19, 2025, Predictive Oncology‘s stockholders approved a one-for-fifteen reverse stock split to comply with Nasdaq’s minimum bid price requirement. The reverse stock split, effective September 29, 2025, will reduce the number of outstanding shares and begin trading on a split-adjusted basis on September 30, 2025. This move aims to maintain the company’s listing on the Nasdaq Capital Market.